Trial Profile
Ertugliflozin in Chronic Heart Failure: Cardio-renal and Diuretic Effects
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary) ; Metolazone
- Indications Chronic heart failure
- Focus Therapeutic Use
- 21 Dec 2023 Planned number of patients changed from 90 to 60.
- 19 Dec 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 19 Dec 2023 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.